Alaska

Alaska

404
Registered Patient Population
0.06%
of Total Population Represented by Patients
93
Total Medical Retail Locations Currently in Operation
4 : 1
Patients : Retail

Alaska law allows patients with a valid card to possess, use, and grow limited amounts of marijuana. There is also an adult-use law. Local governments can ban cannabis business activity, but many in the state have authorized it, including onsite consumption.

Curbside pickup and telemedicine were made available as an option to patients as a response to COVID-19,

ASA recommends modifying the medical marijuana program to provide employment protections for patients, expand the number of plants you can grow, and incentivizing or requiring marijuana businesses to provide products designed for medical applications.

Patient Rights and Civil Protection 65/100   
Arrest Protection 40/40
Affirmative Defense 13/15
Parental Rights Protections 0/10
DUI Protections 0/5
Employment Protections 0/5
Explicit Privacy Standards 7/7
Housing Protections 0/5
Does Not Create New Criminal Penalties for Patients 5/5
Organ Transplants 0/5
Reciprocity 0/3
Access to Medicine 67/100   
Allows Distribution Programs 24/40
– Allows Access to Dried Flowers 15/15
– Allows Delivery 3/5
– No Sales Tax or Reasonable Sales Tax 3/5
– Allows for a Reasonable Number of Dispensaries 1/5
– Does Not Require Vertical Integration 0/2
– Ownership/Employment Restrictions 0/2
– Provisions for Labor Standards 0/2
– Environmental Impact Regulations 0/2
– Choice of Dispensary Without Restrictions 2/2
Noncomercial Cultivation 15/20
– Personal Cultivation 15/15
– Collective Gardening 0/5
Explicit Right to Edibles/Concentrates/Other Forms 0/10
Does not Impose Bans or Limits on THC 10/10
Does not Impose Bans on CBD 10/10
Local Bans/Zoning 8/10
Comprehensive Qualifying Conditions 44/50
Adding New Conditions 7/10
– Law/Regulations Allow for New Conditions 5/5
– System Works for Adding New Conditions 2/5
Reasonable Access for Minors 9/10
Reasonable Caregiver Background Checks 3/4
Number of Caregivers 2/2
Patient/Practitioner-Focused Task Force or Advisory Board 0/2
Reasonable Fees (Patients and Caregivers) 7/10
Allows Multiple-Year Registrations 0/2
Reasonable Physician Requirements 5/5
Does Not Classify Cannabis as a Medicine of Last Resort 3/5
Functionality 74/100   
Patients Able to Access Medicine at Dispensaries or by Cultivation 40/50
No Significant Administrative or Supply Problems 15/15
Patients Can Receive Legal Protections Within Reasonable Time Frame of Doctor's Recommendation 7/10
Reasonable Possession Limits 5/5
Reasonable Purchase Limits 0/5
Allows Patients to Medicate Where They Choose 3/5
Covered by Insurance/State Health Aid 0/3
Financial Hardship (Fee Waivers/Discount Medicine) 4/7
Consumer Safety and Provider Requirements 73/100   
Dispensing 15/25
Staff Training 0/5
Standard Operating Procedures 5/5
– Facility Sanitary Conditions 1.25/1.25
– Storage Protocols 1.25/1.25
– Reasonable Security Protocols 1.25/1.25
– Inventory Control 1.25/1.25
Recall Protocol and Adverse Event Reporting 0/5
Product Labeling 5/5
– Product Contents, Including Source Material Identification 1.67/1.67
– Allergens 1.67/1.67
– Potency/Compound Identification 1.67/1.67
Required Testing 5/5
– Active Compound Identification 1.67/1.67
– Contaminants 1.67/1.67
– Potency 1.67/1.67
Grow/Cultivation 18/25
Staff Training 0/5
Standard Operating Procedures 5/5
– Facility and Equipment Sanitary Conditions 0.71/0.71
– Workforce Safety Protocols 0.71/0.71
– Storage Protocols (Short-Term and Long-Term Storage) 0.71/0.71
– Reasonable Security Protocols 0.71/0.71
– Batch and Lot Tracking 0.71/0.71
– Disposal/Waste 0.71/0.71
– Water Management 0.71/0.71
Pesticide Guidance 3/5
– Pesticide Guidance 3/2.5
– Pesticide Labeling 0/2.5
Required Testing 5/5
– Active Ingredient Identification 1.25/1.25
– Contaminants 1.25/1.25
– Potency 1.25/1.25
– Sample Retention 1.25/1.25
Recall Protocol and Adverse Event Reporting 5/5
Manufacturing 20/25
Staff Training 5/5
Standard Operating Procedures 5/5
– Facility and Equipment Sanitary Conditions 1/1
– Workforce Safety Protocols 1/1
– Storage Protocols 1/1
– Reasonable Security Protocols 1/1
– Batch and Lot Tracking 1/1
Product Labeling 5/5
– Product Contents, Including Source Material Identification 1.67/1.67
– Allergens 1.67/1.67
– Potency and Compound Information 1.67/1.67
Required Testing 5/5
– Active Ingredient Identification 1/1
– Contaminants 1/1
– Potency 1/1
– Shelf Life Testing 1/1
– Sample Retention 1/1
Recall Protocol and Adverse Event Reporting 0/5
Laboratory Operations 20/25
Staff Training 0/5
Method Validation in Accordance with AHP Guidelines 5/5
Result Reporting 5/5
Independent or Third Party 5/5
Standard Operating Procedures and Protocols 5/5
– Equipment and Instrument Calibration 0.83/0.83
– Sample Tracking 0.83/0.83
– Facility and Equipment Sanitary Conditions 0.83/0.83
– Disposal/Waste 0.83/0.83
– Storage Protocols 0.83/0.83
– Workforce Safety Protocols 0.83/0.83
Covid Response 12/20   
Delivery Available? 0/6
Curbside Pickup Available? 2/2
Medical Cannabis Essential? 7/7
Telemedicine Available? 3/5
Excerpted from ASA's 2020 State of the States Report.

In This Section

The State of Medical Marijuana in Alaska

The State of Medical Marijuana in Alaska